Tarsus Pharmaceuticals Inc (TARS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has a cash flow conversion efficiency ratio of -0.071x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.65 Million) by net assets ($348.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TARS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Tarsus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tarsus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SASA Polyester Sanayi AS
IS:SASA
|
0.052x |
|
Ebos Group Ltd
AU:EBO
|
0.017x |
|
5N Plus Inc.
TO:VNP
|
-0.061x |
|
Double Medical Technology Inc
SHE:002901
|
0.054x |
|
President Securities Corp
TW:2855
|
-0.017x |
|
Companhia de Gás de São Paulo - COMGÁS
SA:CGAS3
|
0.555x |
|
Artisan Partners Asset Management Inc
NYSE:APAM
|
0.354x |
|
Customers Bancorp, Inc.
NYSE:CUBI
|
0.016x |
Annual Cash Flow Conversion Efficiency for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see TARS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $343.43 Million | $-12.45 Million | -0.036x | +90.20% |
| 2024-12-31 | $224.53 Million | $-83.03 Million | -0.370x | +38.00% |
| 2023-12-31 | $196.99 Million | $-117.49 Million | -0.596x | -134.66% |
| 2022-12-31 | $192.90 Million | $-49.03 Million | -0.254x | -1230.69% |
| 2021-12-31 | $166.73 Million | $3.75 Million | 0.022x | +117.65% |
| 2020-12-31 | $165.98 Million | $-21.14 Million | -0.127x | -120.82% |
| 2019-12-31 | $-6.00 Million | $-3.67 Million | 0.612x | -29.99% |
| 2018-12-31 | $-1.35 Million | $-1.18 Million | 0.874x | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more